Peer Review Committee for Cancer Drug Discovery (CDD)

Areas reviewed: Chemical studies dealing with the modification or development of drugs. Preclinical studies involving toxicity and effectiveness, and the development of drug delivery systems. Pharmacological studies, and studies involving nuclear magnetic resonance and crystallography, on the mechanisms of drug action, and the application of this information to drug design. Studies on the isolation, testing, and synthesis of natural therapeutic agents.

Joseph Kissil, PhD, Chair
Scripps Research Institute
Jupiter, FL

Eric B. Haura, MD, Vice-Chair
Moffitt Cancer Center
Tampa, FL

Susan Clawson, Stakeholder
Braintree, MA

M. Laird Forrest, PhD
University of Kansas
Lawrence, KS

Balasz Halmos, MD
Albert Einstein College of Medicine, Yeshiva University
Bronx, NY

Geoffrey Hird, PhD
Liquidia Technologies, Inc.
Morrisville, NC

Mark Kester, PhD
University of Virginia
Charlottesville, VA

Joerg Lahann, PhD
University of Michigan
Ann Arbor, MI

Tambre Leighn, MA, Stakeholder
Shrewsbury, NJ

Samy Meroueh, PhD
Indiana University
Indianapolis, IN

David Wald, PhD, MD
Case Western Reserve University
Cleveland, OH

Susan Wee, PhD
Bristol-Myers Squibb Company
Princeton, NJ